468 related articles for article (PubMed ID: 19237579)
1. Lipocalin 2 promotes breast cancer progression.
Yang J; Bielenberg DR; Rodig SJ; Doiron R; Clifton MC; Kung AL; Strong RK; Zurakowski D; Moses MA
Proc Natl Acad Sci U S A; 2009 Mar; 106(10):3913-8. PubMed ID: 19237579
[TBL] [Abstract][Full Text] [Related]
2. Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer.
Ding G; Fang J; Tong S; Qu L; Jiang H; Ding Q; Liu J
Prostate; 2015 Jun; 75(9):957-68. PubMed ID: 25728945
[TBL] [Abstract][Full Text] [Related]
3. Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway.
Wang YP; Yu GR; Lee MJ; Lee SY; Chu IS; Leem SH; Kim DG
Hepatology; 2013 Oct; 58(4):1349-61. PubMed ID: 23696034
[TBL] [Abstract][Full Text] [Related]
4. Lipocalin 2: a multifaceted modulator of human cancer.
Yang J; Moses MA
Cell Cycle; 2009 Aug; 8(15):2347-52. PubMed ID: 19571677
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor (ER)α-regulated lipocalin 2 expression in adipose tissue links obesity with breast cancer progression.
Drew BG; Hamidi H; Zhou Z; Villanueva CJ; Krum SA; Calkin AC; Parks BW; Ribas V; Kalajian NY; Phun J; Daraei P; Christofk HR; Hewitt SC; Korach KS; Tontonoz P; Lusis AJ; Slamon DJ; Hurvitz SA; Hevener AL
J Biol Chem; 2015 Feb; 290(9):5566-81. PubMed ID: 25468909
[TBL] [Abstract][Full Text] [Related]
6. Lipocalin 2, the TNF-like receptor TWEAKR and its ligand TWEAK act downstream of NFAT1 to regulate breast cancer cell invasion.
Gaudineau B; Fougère M; Guaddachi F; Lemoine F; de la Grange P; Jauliac S
J Cell Sci; 2012 Oct; 125(Pt 19):4475-86. PubMed ID: 22767506
[TBL] [Abstract][Full Text] [Related]
7. ERalpha signaling through slug regulates E-cadherin and EMT.
Ye Y; Xiao Y; Wang W; Yearsley K; Gao JX; Shetuni B; Barsky SH
Oncogene; 2010 Mar; 29(10):1451-62. PubMed ID: 20101232
[TBL] [Abstract][Full Text] [Related]
8. Lipocalin 2 promotes the migration and invasion of esophageal squamous cell carcinoma cells through a novel positive feedback loop.
Du ZP; Wu BL; Xie YM; Zhang YL; Liao LD; Zhou F; Xie JJ; Zeng FM; Xu XE; Fang WK; Li EM; Xu LY
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2240-50. PubMed ID: 26190820
[TBL] [Abstract][Full Text] [Related]
9. Thyroid hormone-mediated regulation of lipocalin 2 through the Met/FAK pathway in liver cancer.
Chung IH; Chen CY; Lin YH; Chi HC; Huang YH; Tai PJ; Liao CJ; Tsai CY; Lin SL; Wu MH; Chen CY; Lin KH
Oncotarget; 2015 Jun; 6(17):15050-64. PubMed ID: 25940797
[TBL] [Abstract][Full Text] [Related]
10. Notch1 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-dependent manner.
Shao S; Zhao X; Zhang X; Luo M; Zuo X; Huang S; Wang Y; Gu S; Zhao X
Mol Cancer; 2015 Feb; 14(1):28. PubMed ID: 25645291
[TBL] [Abstract][Full Text] [Related]
11. NFAT3 transcription factor inhibits breast cancer cell motility by targeting the Lipocalin 2 gene.
Fougère M; Gaudineau B; Barbier J; Guaddachi F; Feugeas JP; Auboeuf D; Jauliac S
Oncogene; 2010 Apr; 29(15):2292-301. PubMed ID: 20101218
[TBL] [Abstract][Full Text] [Related]
12. Lipocalin 2 expression is associated with aggressive features of endometrial cancer.
Mannelqvist M; Stefansson IM; Wik E; Kusonmano K; Raeder MB; Øyan AM; Kalland KH; Moses MA; Salvesen HB; Akslen LA
BMC Cancer; 2012 May; 12():169. PubMed ID: 22559235
[TBL] [Abstract][Full Text] [Related]
13. Lipocalin2 enhances the matrix metalloproteinase-9 activity and invasion of extravillous trophoblasts under hypoxia.
Kobara H; Miyamoto T; Suzuki A; Asaka R; Yamada Y; Ishikawa K; Kikuchi N; Ohira S; Shiozawa T
Placenta; 2013 Nov; 34(11):1036-43. PubMed ID: 23972287
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis.
Leng X; Ding T; Lin H; Wang Y; Hu L; Hu J; Feig B; Zhang W; Pusztai L; Symmans WF; Wu Y; Arlinghaus RB
Cancer Res; 2009 Nov; 69(22):8579-84. PubMed ID: 19887608
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer.
Kurozumi S; Alsaeed S; Orah N; Miligy IM; Joseph C; Aljohani A; Toss MS; Fujii T; Shirabe K; Green AR; Aleskandarany MA; Rakha EA
Breast Cancer Res Treat; 2020 Feb; 179(3):557-564. PubMed ID: 31707510
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic induction of epithelial to mesenchymal transition by LCN2 mediates metastasis and tumorigenesis, which is abrogated by NF-κB inhibitor BRM270 in a xenograft model of lung adenocarcinoma.
Mongre RK; Sodhi SS; Sharma N; Ghosh M; Kim JH; Kim N; Park YH; Shin YG; Kim SJ; Jiao ZJ; Huynh do L; Jeong DK
Int J Oncol; 2016 Jan; 48(1):84-98. PubMed ID: 26573874
[TBL] [Abstract][Full Text] [Related]
17. HIC1 silencing in triple-negative breast cancer drives progression through misregulation of LCN2.
Cheng G; Sun X; Wang J; Xiao G; Wang X; Fan X; Zu L; Hao M; Qu Q; Mao Y; Xue Y; Wang J
Cancer Res; 2014 Feb; 74(3):862-72. PubMed ID: 24295734
[TBL] [Abstract][Full Text] [Related]
18. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer.
Vuoriluoto K; Haugen H; Kiviluoto S; Mpindi JP; Nevo J; Gjerdrum C; Tiron C; Lorens JB; Ivaska J
Oncogene; 2011 Mar; 30(12):1436-48. PubMed ID: 21057535
[TBL] [Abstract][Full Text] [Related]
19. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer.
Guo BH; Feng Y; Zhang R; Xu LH; Li MZ; Kung HF; Song LB; Zeng MS
Mol Cancer; 2011 Jan; 10(1):10. PubMed ID: 21276221
[TBL] [Abstract][Full Text] [Related]
20. Lipocalin 2 is essential for chronic kidney disease progression in mice and humans.
Viau A; El Karoui K; Laouari D; Burtin M; Nguyen C; Mori K; Pillebout E; Berger T; Mak TW; Knebelmann B; Friedlander G; Barasch J; Terzi F
J Clin Invest; 2010 Nov; 120(11):4065-76. PubMed ID: 20921623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
